
PASSAGE BIO (PASG) Stock Forecast & Price Target
PASSAGE BIO (PASG) Analyst Ratings
Bulls say
Passage Bio Inc is focused on developing innovative therapies for rare, monogenic CNS disorders, with products addressing conditions such as GM1 Gangliosidosis and Frontotemporal dementia. Recent interim data suggest PBFT02 demonstrates sustained efficacy, marked by a mean cerebrospinal fluid (CSF) progranulin increase and an overall positive trajectory in biomarker improvements, which may facilitate regulatory approval and reduce trial duration. Moreover, the strategic design of its registrational trials, which may pursue approval based on biomarkers alone, positions Passage Bio favorably to capitalize on potential advancements in genetic medicine.
Bears say
The financial outlook for Passage Bio Inc is negatively impacted by various clinical and regulatory risks associated with its gene therapy programs. The potential for delays in clinical timelines and the emergence of unforeseen safety signals raise significant concerns regarding market sentiment and may lead to downward revisions in financial estimates. Moreover, insufficient manufacturing capacity poses an additional risk that could materially constrain the company's forecasts and hinder its ability to deliver on its developmental targets.
This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.
PASSAGE BIO (PASG) Analyst Forecast & Price Prediction
Start investing in PASSAGE BIO (PASG)
Order type
Buy in
Order amount
Est. shares
0 shares